Immunic (NASDAQ:IMUX) Stock Gets Downgrade from Zacks Research

Immunic (NASDAQ:IMUX) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Ladenburg Thalmann & Co. Inc. raised Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.43.

Immunic Stock Performance

NASDAQ:IMUX opened at $8.12 on Tuesday. The firm has a market cap of $110.79 million, a price-to-earnings ratio of -1.85 and a beta of 1.48. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43. The firm has a 50-day moving average price of $8.93 and a two-hundred day moving average price of $11.51.

Immunic (NASDAQ:IMUX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. As a group, sell-side analysts forecast that Immunic will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Immunic by 21.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock worth $69,000 after acquiring an additional 1,400 shares during the period. Alps Advisors Inc. grew its position in shares of Immunic by 28.0% in the third quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after purchasing an additional 3,870 shares in the last quarter. CTC Alternative Strategies Ltd. purchased a new position in shares of Immunic in the first quarter valued at $27,000. ADAR1 Capital Management LLC bought a new stake in shares of Immunic during the 1st quarter valued at $33,000. Finally, Bank of America Corp DE raised its stake in shares of Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies. Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.